



## Product Information

### Integrin inhibitor, GLPG0187, Purity $\geq 98\%$

**Cat. No.:** X24-08-YM287

**Size:** 1 mg; 5 mg; 10 mg; 50 mg

**CAS Number:** 1320346-97-1


**Compound CID:** 53340771

**Synonym:** 1320346-97-1; GLPG 0187; GLPG-0187;

(2S

)-3-[[2,5-Dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl]pyrimidin

-4-yl]amino]-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid



**This product is for research use only and is not intended for diagnostic use.**

### Product Information

|                          |                                                                                                                                                                                                                                     |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Description</b>       | GLPG0187 is an effective cytoskeleton inhibitor, that has the ability to prevent the pathway of cytoskeletal signaling by inhibiting integrin.                                                                                      |
| <b>Molecular Weight</b>  | 595.71                                                                                                                                                                                                                              |
| <b>Molecular Formula</b> | C <sub>29</sub> H <sub>37</sub> N <sub>7</sub> O <sub>5</sub> S                                                                                                                                                                     |
| <b>IUPAC Name</b>        | (2S)-3-[[2,5-Dimethyl-6-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)piperidin-1-yl]pyrimidin-4-yl]amino]-2-[(4-methoxyphenyl)sulfonylamino]propanoic acid                                                                          |
| <b>InChI</b>             | InChI=1S/C29H37N7O5S/c1-18-26(31-17-25(29(37)38)35-42(39,40)23-9-7-22(41-3)8-10-23)32-19(2)33-28(18)36-15-12-20(13-16-36)24-11-6-21-5-4-14-30-27(21)34-24/h6-11,20,25,35H,4-5,12-17H2,1-3H3,(H,30,34)(H,37,38)(H,31,32,33)/t25-m/s1 |
| <b>InChI Key</b>         | CXHCNOMGODVIKB-VWLOTQADSA-N                                                                                                                                                                                                         |
| <b>Canonical SMILES</b>  | CC1=C(N=C(N=C1N2CCC(CC2)C3=NC4=C(CCCN4)C=C3)C)NCC(C(=O)O)NS(=O)(=O)C5=CC=C(C=C5)OC                                                                                                                                                  |
| <b>Isomeric SMILES</b>   | CC1=C(N=C(N=C1N2CCC(CC2)C3=NC4=C(CCCN4)C=C3)C)NC[C@@H](C(=O)O)NS(=O)(=O)C5=CC=C(C=C5)OC                                                                                                                                             |
| <b>Form</b>              | Lyophilized powder                                                                                                                                                                                                                  |
| <b>Purity</b>            | $\geq 98\%$                                                                                                                                                                                                                         |
| <b>Titer</b>             | Free from inappropriate visible particulates, foreign matter, discoloration, or other defects                                                                                                                                       |
| <b>Stability</b>         | In its lyophilized form, the chemical remains stable for 36 months.                                                                                                                                                                 |
| <b>Quality Level</b>     | Research grade                                                                                                                                                                                                                      |



---

**Applications**

GLPG0187 is a cytoskeletal signaling inhibitor that can be studied extensively for its potential therapeutic applications in the treatment of fibrotic diseases and certain cancers by targeting  $\alpha\text{v}\beta 6$  integrin, which is involved in tissue fibrosis and cancer progression.

---

**Storage**

Store at  $-20^{\circ}\text{C}$ , and keep desiccated.

---